Table 1.
Clinical Characteristics based on Early Regression of Severe LVH after TAVR
| TAVR A (RCT + NRCA) n=690 |
|||
|---|---|---|---|
| Greater LVMi Regression (n=344) |
Lesser LVMi Regression (n=346) |
p-value | |
| Age | 85.5 ± 6.1 | 84.7 ± 6.9 | 0.11 |
| Female | 56% | 56% | 0.99 |
| Body mass index (kg/m2) | 25.8 ± 5.5 | 27.0 ± 6.4 | 0.009 |
| Obesity (BMI ≥30) | 18.9% | 25.1% | 0.05 |
| Body surface area (m2) | 1.74 ± 0.23 | 1.78 ± 0.24 | 0.02 |
| STS Score | 11.7 ± 3.9 | 12.3 ± 5.6 | 0.08 |
| STS >10 | 68% | 70% | 0.44 |
| Logistic EuroSCORE | 28.0 ± 15.8 | 28.7 ± 17.3 | 0.58 |
| Hyperlipidemia | 83% | 83% | 0.95 |
| Smoking | 45% | 47% | 0.64 |
| Hypertension | 92% | 95% | 0.21 |
| Diabetes mellitus | 34% | 41% | 0.056 |
| NYHA class 4 | 47% | 46% | 0.88 |
| Angina | 16% | 20% | 0.21 |
| Coronary disease | 74% | 78% | 0.23 |
| Prior myocardial infarction | 29% | 30% | 0.84 |
| Prior PCI | 42% | 38% | 0.26 |
| Prior coronary artery bypass surgery | 41% | 46% | 0.16 |
| Stroke or TIA (last 6–12 months) | 26% | 31% | 0.10 |
| Carotid disease | 27% | 30% | 0.42 |
| Peripheral vascular disease | 43% | 43% | 0.96 |
| Porcelain aorta | 0.3% | 0.9% | 0.62 |
| Pulmonary hypertension | 42% | 40% | 0.59 |
| Major arrhythmia | 49% | 55% | 0.09 |
| Permanent pacemaker | 18% | 26% | 0.01 |
| Renal disease (creatinine ≥2) | 16% | 20% | 0.15 |
| Liver disease | 1.7% | 2.0% | 0.79 |
| Chronic obstructive lung disease | 38% | 41% | 0.43 |
| Oxygen dependent | 8.1% | 7.8% | 0.87 |
| Anemia | 71% | 69% | 0.52 |
| Transfemoral TAVR | 53% (182/344) | 58% (200/346) | 0.20 |
Greater vs. lesser LVMi regression defined by sex-specific median % change in LVMi from baseline to 30 days post-TAVR.
Abbreviations: TAVR, transcatheter aortic valve replacement; RCT, randomized controlled trial; NRCA, non-randomized continued access registry; LVMi, left ventricular mass index; BMI, body mass index; STS, Society of Thoracic Surgery; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.